Cellceutix enters into a $30 million common stock purchase agreement
Cellceutix announced it has signed a $30 million stock purchase agreement with Aspire Capital Fund. Aspire has committed to purchase over the next 3 years up to $30 million of Cellceutix's common stock based on the prevailing market prices at the time of each sale. April 01, 2015